| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/HMG/DDI095 |
| P698 | PubMed publication ID | 15757977 |
| P50 | author | Jeffrey Miller | Q42613275 |
| P2093 | author name string | Mary Lou Beermann | |
| Amanda J Kravetz | |||
| Christine A Kostek | |||
| Janice A Dominov | |||
| Magdalena Ardelt | |||
| P433 | issue | 8 | |
| P304 | page(s) | 1029-1040 | |
| P577 | publication date | 2005-03-09 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice | |
| P478 | volume | 14 |
| Q49571085 | Aberrant Caspase Activation in Laminin-α2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity. |
| Q54210538 | Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin. |
| Q39559269 | Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). |
| Q37612532 | Apoptosis in differentiating C2C12 muscle cells selectively targets Bcl-2-deficient myotubes |
| Q24602606 | Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice |
| Q28585764 | BAG3 deficiency results in fulminant myopathy and early lethality |
| Q33995531 | Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy |
| Q37085050 | Biology of the striated muscle dystrophin-glycoprotein complex |
| Q35657951 | Bit-1 is an essential regulator of myogenic differentiation |
| Q37738318 | Congenital muscular dystrophies: toward molecular therapeutic interventions |
| Q45865539 | Congenital muscular dystrophy: mini-agrin delivers in mice |
| Q91906240 | Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy |
| Q34200139 | Ex vivo stretch reveals altered mechanical properties of isolated dystrophin-deficient hearts |
| Q37785124 | Genetic Defects in Muscular Dystrophy |
| Q37531866 | Immortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research |
| Q24644090 | Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy |
| Q28534074 | Isobaric Tagging-Based Quantification for Proteomic Analysis: A Comparative Study of Spared and Affected Muscles from mdx Mice at the Early Phase of Dystrophy |
| Q37411771 | Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. |
| Q94544460 | LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models |
| Q35274694 | Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A. |
| Q36118063 | Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages |
| Q35750207 | Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. |
| Q53180281 | Molecular hydrogen alleviates motor deficits and muscle degeneration in mdx mice. |
| Q34994784 | Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A |
| Q34218839 | MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3 |
| Q34769964 | Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy |
| Q34597868 | Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy |
| Q37257159 | Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice |
| Q35928246 | Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. |
| Q34285775 | P38α MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism |
| Q37091285 | Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy |
| Q35030852 | Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy. |
| Q34152280 | Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials |
| Q35440708 | Proinflammatory Signals and the Loss of Lymphatic Vessel Hyaluronan Receptor-1 (LYVE-1) in the Early Pathogenesis of Laminin Alpha2-deficient Skeletal Muscle |
| Q35572589 | SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models |
| Q36196509 | SIRT1-dependent myoprotective effects of resveratrol on muscle injury induced by compression. |
| Q22001192 | Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies |
| Q36592193 | The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis |
| Q37021293 | The role of cell death in sexually dimorphic muscle development: male-specific muscles are retained in female bax/bak knockout mice |
| Q24681141 | The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy |
| Q37138490 | Wasting mechanisms in muscular dystrophy. |
Search more.